Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

Clinical trial NCT06423326 · RECRUITING

Trial details

NCT number: NCT06423326
Sponsor: Emory University
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Borderline Resectable Pancreatic Ductal Adenocarcinoma Resectable Pancreatic Adenocarcinoma Stage I Pancreatic Cancer AJCC v8 Stage II Pancreatic Cancer AJCC v8 Stage III Pancreatic Cancer AJCC v8

Start date: 2024-08-06
Primary completion: 2026-12-31
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.